PROPEL

PROPEL – NOW Enrolling!

PROPEL is a first-in-human study designed to assess the safety of SBT101, a novel, investigational gene therapy intended to treat adrenomyeloneuropathy (AMN). The study will also explore how SBT101 may affect the progression of AMN.

What is SBT101?



- SBT101 is an investigational gene therapy which is intended to use the person's spinal cord cells to create working copies of the ABCD1 protein, which is missing or impaired in people with AMN.
- SBT101 is an *in vivo* gene therapy, which means it can be administered directly to the patient by infusion.

AAV, adeno-associated virus.
Image adapted from Li C, Samulski RJ. *Nat Rev Genet*. 2020;21(4):255-272.

Am I eligible for this study?

- Are you a male between the ages of 18 and 65 years old?
- Have you received a definitive diagnosis of AMN?
- Do you have symptoms of AMN but are still able to walk independently?

If you answer yes to all of these questions you may be eligible to participate. Please note individuals with evidence of cerebral inflammatory disease, which may occur with AMN, cannot participate in this study.

What is expected of me if I participate?

- You will need to undergo a lumbar puncture (spinal tap) as part of the administration procedure.
- SBT101 is administered only once and will be infused into your spine through a catheter by trained staff.
- You will visit the clinic regularly and have periodic phone calls with the study staff for 2 years (the main part of the study). After the initial 2 years, you will visit the clinic annually through 5 years (long term follow-up).

Where can I learn more about the PROPEL study?

If you are interested in more information, you can speak with your doctor or contact clinicaltrials@swanbiotx.com, call (267) 417-6356, or go to www.clinicaltrials.gov:NCT05394064.

ABOUT SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. Driven by a sense of urgency for patients, we are advancing a pipeline of AAV-based gene therapies, designed to be delivered intrathecally, to address targets within both the central and peripheral nervous systems.

Learn more at swanbiotx.com

REFERENCE
SwanBio Therapeutics, Ltd. Phase 1/2 Clinical research protocol. SBT101-CT101. Version 2; 09 March 2022. Accessed May 11, 2022.

SwanBio THERAPEUTICS